Clinical Sample Collection COVID19 Patients to Align with NIAID National Study

The NIAID national protocol intends to enroll at least 1000 COVID19 patients in a study designed to track infectedpatients through tracking, over time, their immune responses, viral load, and a variety of multi-omic analytes thatcan provide deep insights into how infection by SARS-CoV-2 is revealed in host defense responses and disease-perturbed networks. At the heart of this study is the establishment of high quality biorepositories that can beused to quantitatively assess viral load, quantitatively interrogate viable PBMCs, and permit direct comparisonsbetween different patients and different time points of disease progression. The nature of the infection, withhighly differential patient outcomes, will eventually require significant computational efforts that can account forconfounding factors such as co-morbidities, the influence of various therapies that are being broadly tested inthese patients, etc. It will also almost certainly require all 1000 projected patients, if not more, to resolve someof the most outstanding and urgent clinical questions. However, all of these results rely on establishing highquality biobanks, resource sharing, and data sharing. This is an area in which the ISB has deep expertise andis excited to contribute. The ISB and SMC launched a joint study designed to enroll 200 COVID19 patientsaround 3/20/2020. That study has overlap with the NIAID protocol and shares a common set of over-archinggoals. Here we propose to increase that overlap and to make that accruing biobank of COVID19 patientspecimens and associated characterization data a national resource through inclusion in the NIAID protocol.